Sr. Clinician Emergency Medicine, and Internal Medicine, Board Certified

Internal Medicine

Doctor Michael F. Doubek, MD is an expert in the field of Internal Medicine. He studied medicine at Saint Louis University School of Medicine. Saint Louis University School of Medicine is ranked 67/57 in Research/PrimaryCare. Michael Doubek is a published MD. He published 67 publications, including: 'Must we really fear toxicity of conventional amphotericin B in oncological patients?'

Publications

---

• miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities.
• The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group.
• [The POEMS syndrome: a case report].
• [Discovery of blood cells in the 17th century].
• A note on the decreased number and loss of fibrillar centres in nucleoli of apoptotic HL-60 leukaemic granulocytic precursors produced by 5-aminolaevulinic acid-based ...
• Megakaryocyte colony-forming unit growth is enhanced by alemtuzumab: in vitro experiments and a case report of acquired amegakaryocytic thrombocytopenic purpura.
• [Who was Mr. McBean and what resulted from his death?].
• [A patient with Madelung''s disease at the internal medicine department].
• [Universities need to have high quality education as well as an effective quality control of their students'' (products'') knowledge and skill base].
• [Hematologic malignancies in pregnancy].
• [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].
• [Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].
• Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment.
• Current role of immunotherapy in multiple myeloma.
• Interleukin-2 activation of haematopoietic stem cells.
• Microarray analysis using a limited amount of cells.
• Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia.
• [Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
• [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
• [Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1...
• [What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be t...
• Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia.
• [Collection of peripheral hematopoietic stem cells for transplantation from volunteer donors--siblings of the patients].
• [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
• Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL.
• Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
• Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy.
• [Lymphocytosis with large granular lymphocytes: case report].
• [Rare diagnosis of CD4+56+ leukemia from dendritic cells type DC2].
• Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
• [High-dosage chemotherapy with support of autologous haematopoietic cells in the treatment of multiple myeloma--review of contemporary possibilities].
• [Must we be really concerned about amphotericin B toxicity in oncology patients?].
• Must we really fear toxicity of conventional amphotericin B in oncological patients?
• Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study.
• [Therapy of chronic myeloid leukemia. Uncommon view of the modern approaches].
• Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
• [Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases].
• [Treatment of adult acute lymphoblastic leukemia according to GMALL 07/2003 study protocol in the Czech Republic - the first experience].
• Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukem...
• [Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics].
• [Detection of myeloma cells in peripheral blood using multi-parameter flow cytometry: monitoring residual disease].
• [Hereditary thrombocytopenia. Differential diagnosis of a case].
• Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
• Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
• [Activation of autologous hematopoietic stem cell transplants with interleukin-2].
• Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
• [Safety of long-term administration of conventional amphotericin B in oncology patients].
• [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation...
• [Molecular genetic characterization of chronic lymphocytic leukemia aggressivity in Czech patients: a nucleotide variability of genes coding for heavy chain of immunog...
• Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
• Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia.
• [Lymphoproliferative disease in patients with autoimmune and inflammatory diseases: significance of antigenic stimulation and inflammatory processes].
• Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.
• Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinic...
• Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CE...
• Retrospective survey on the prevalence and outcome of prior autoimmune diseases in patients with aplastic anemia reported to the registry of the European group for blo...
• Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
• A case of a novel PML/RARA short fusion transcript with truncated transcription variant 2 of the RARA gene.
• High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (I...
• Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide.
• Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecul...
• Retention of nanoparticles-labeled bone marrow mononuclear cells in the isolated ex vivo perfused heart after myocardial infarction in animal model.
• Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion.
• Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient.
• Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
• Intracoronary delivery of bone marrow cells to the acutely infarcted myocardium. Optimization of the delivery technique.

Schools

---

• Saint Louis University School Of Medicine

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

Education

---

• St Louis University School of Medicine
• Saint Louis University School of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Scott W. Burk, MD This Doctor is OpenDoctor Recommended.
	Dr. Stacy M. Kingsland, MD This Doctor is OpenDoctor Recommended.
	Dr. Tony J. Lenz, MD This Doctor is OpenDoctor Recommended.
	Dr. Steven M. Chrzanowski, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas B. Addison, MD This Doctor is OpenDoctor Recommended.
	Dr. Hassan H. Tabrizi, MD This Doctor is OpenDoctor Recommended.
	Dr. Bobby L. Maynard, MD This Doctor is OpenDoctor Recommended.
	Dr. Nishan Dallakoti, MD This Doctor is OpenDoctor Recommended.
	Dr. Mojabeng Phoofolo, MD This Doctor is OpenDoctor Recommended.
	Dr. Ramesh C. Yarlagadda, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog